Literature DB >> 7911124

Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors.

P J Ho1, C A Jaffe, R D Friberg, W F Chandler, A L Barkan.   

Abstract

GH concentration profiles in patients with acromegaly are characterized by rapid GH pulsatility and high interpulse GH concentrations. Animal and human studies have shown that GH pulses are consequent upon periodic discharges of hypothalamic GHRH, whereas interpulse GH levels might reflect tonic secretion of hypothalamic SRIH. Thus, the pattern of GH secretion in acromegaly may conceivably be attributed to high GHRH pulse frequency and/or SRIH deficiency. If this assumption is correct, removal of a GH-producing tumor should be followed by a persistently high GH pulse frequency and a high recurrence rate. We have studied pulsatile GH secretion in 12 patients with acromegaly before and after apparently complete removal of their pituitary tumors. Despite normalization of GH secretion after surgery, the disease recurred in 3 patients within 3 yr. The other 9 patients had normal insulin-like growth factor-I and basal and dynamic GH concentrations for 24 +/- 4 months postsurgery. Parameters of GH secretion in this group (pre- and postsurgery) were compared to sex-, age-, and body mass index-matched controls. Plasma GH concentrations in the postoperative and control series were analyzed by a chemiluminescent assay with a sensitivity of 0.01 micrograms/L. Removal of the somatotroph tumor led to normalization of mean and interpulse (but not the nadir) GH levels, pulse amplitude, and responses to GHRH. However, GH pulse frequency (14.2 +/- 1.2 vs. 11.8 +/- 0.9 pulses/24 h) did not change and was significantly (P < 0.001) higher than the control value (8.7 +/- 0.9 pulses/24 h). Thus, SRIH secretion in acromegaly is not inherently deficient, and high interpulse GH levels reflect the mass of tumorous somatotrophs. The persistence of rapid GH pulsatility in apparently "cured" patients with acromegaly suggests that abnormally rapid GHRH pulsatility may be an inherent component of the disease process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911124     DOI: 10.1210/jcem.78.6.7911124

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score.

Authors:  H Jasper; P Pennisi; M Vitale; A Mella; G Ropelato; A Chervin
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients.

Authors:  Laura Boero; Marcos Manavela; Karina Danilowicz; Analia Alfieri; Maria Carolina Ballarino; Alberto Chervin; Natalia García-Basavilbaso; Mariela Glerean; Mirtha Guitelman; Monica Graciela Loto; Jose Alberto Nahmías; Amelia Susana Rogozinski; Marisa Servidio; Nicolas Marcelo Vitale; Débora Katz; Patricia Fainstein Day; Graciela Stalldecker; Maria Susana Mallea-Gil
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly.

Authors:  Raquel S Jallad; Ericka B Trarbach; Felipe H Duarte; Alexander A L Jorge; Marcello D Bronstein
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 4.  Growth hormone pulsatility in acromegaly following radiotherapy.

Authors:  S R Peacey; S M Shalet
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

5.  Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models.

Authors:  Katica Bajuk Studen; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

Review 6.  Current diagnosis of acromegaly.

Authors:  Rocio A Cordero; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 7.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

Review 8.  Serum IGF-I levels in the diagnosis and monitoring of acromegaly.

Authors:  A M Brooke; W M Drake
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

Review 9.  Defining normalcy of the somatotropic axis: an attainable goal?

Authors:  Ariel L Barkan
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.